Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview
04:05pm, Wednesday, 05'th Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. “Acadia delivered another strong quarter,
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
11:01am, Wednesday, 29'th Oct 2025
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mutual of America Capital Management LLC Sells 2,020 Shares of ACADIA Pharmaceuticals Inc. $ACAD
04:00am, Wednesday, 29'th Oct 2025
Mutual of America Capital Management LLC cut its stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 11.3% in the undefined quarter, according to its most recent filing with the Securities and Exch
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
04:05pm, Tuesday, 28'th Oct 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Mo
Acadia (ACAD) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Tuesday, 28'th Oct 2025
Acadia (ACAD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Acadia (ACAD) Have the Potential to Rally 27.66% as Wall Street Analysts Expect?
10:55am, Tuesday, 28'th Oct 2025
The mean of analysts' price targets for Acadia (ACAD) points to a 27.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10:00am, Tuesday, 28'th Oct 2025
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
11:00am, Thursday, 23'rd Oct 2025
NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are adv
Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights
03:41pm, Wednesday, 22'nd Oct 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
10:00am, Saturday, 18'th Oct 2025
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are a
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 15'th Oct 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
01:42pm, Monday, 13'th Oct 2025
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are adv
QGEN vs. ACAD: Which Stock Is the Better Value Option?
12:41pm, Thursday, 09'th Oct 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value inv
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
04:36pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advi
ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish
07:30am, Monday, 06'th Oct 2025
ACAD's thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD's Q2 2025 revenues remain solid with Nuplazid and Daybu
